Cardiomyopathies: Classification, Diagnosis, and Treatment

Heart Failure Clinics

Volumn 8, Issue 1, 2012, Pages 53-78

  Maisch, Bernhard ^a   Noutsias, Michel ^b   Ruppert, Volker ^b   Richter, Anette ^b   Pankuweit, Sabine ^b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UKGM GmbH   (Germany)

Author keywords

Cardiomyopathies; Hypertrophic cardiomyopathy; Myocarditis; Restrictive cardiomyopathy; Right ventricular cardiomyopathy

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTIARRHYTHMIC AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CORTICOSTEROID; CYCLOSPORIN; GADOLINIUM; IMMUNOGLOBULIN; INTERFERON; SMALLPOX VACCINE; TROPONIN I;

ADENOVIRUS; ANGIOGRAPHY; CARDIOMEGALY; CATHETER ABLATION; CHICKENPOX; CLINICAL ASSESSMENT; COMPLETE HEART BLOCK; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL (TOPIC); CYTOMEGALOVIRUS INFECTION; DEFIBRILLATOR; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; ENTEROVIRUS INFECTION; GENE MUTATION; GENETIC LINKAGE; GENETIC SCREENING; HEART CATHETERIZATION; HEART INFARCTION; HEART MUSCLE BIOPSY; HEART MUSCLE NECROSIS; HEART OUTFLOW TRACT OBSTRUCTION; HEART PAPILLARY MUSCLE; HEART RIGHT VENTRICLE DYSPLASIA; HEPATITIS; HERPES VIRUS INFECTION; HUMAN; HUMAN HERPESVIRUS 6; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN PARVOVIRUS B19; HYPERTROPHIC CARDIOMYOPATHY; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IN SITU HYBRIDIZATION; INFECTIOUS MONONUCLEOSIS; INFLUENZA; ISCHEMIC CARDIOMYOPATHY; MITOCHONDRIAL MYOPATHY; MUMPS; NUCLEAR MAGNETIC RESONANCE IMAGING; PARVOVIRUS INFECTION; POLIOMYELITIS; POLYMERASE CHAIN REACTION; PROGNOSIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RESTRICTIVE CARDIOMYOPATHY; REVIEW; RUBELLA; SARCOMERE; SERODIAGNOSIS; SMALLPOX; TAKOTSUBO CARDIOMYOPATHY; VACCINIA; VALSALVA MANEUVER; VIRUS GENOME; VIRUS MYOCARDITIS;

BIOMEDICAL RESEARCH; CARDIOLOGY; CARDIOMYOPATHIES; HUMANS; SOCIETIES, MEDICAL;

EID: 82955193154     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2011.08.014     Document Type: Review

References (147)

1. Kerr W.W. Myocarditis. Cal State J Med 1904, 2:369-371.
2. Hickie J.B., Hall G.V. The cardiomyopathies: a report of fifty cases. Australas Ann Med 1960, 9:258-270.
3. Goodwin J.F., Gordon H., Hollman A., et al. Clinical aspects of cardiomyopathy. Br Med J 1961, 1:69-79.
4. Report of the WHO/ISFC Task Force on the definition and classification of cardiomyopathies. Br Heart J 1980, 44:672-674.
5. Richardson P., McKenna W., Bristow M., et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation 1996, 93:841-842.
6. Maisch B., Bültman B., Factor S., et al. World Heart Federation consensus conference's definition of inflammatory cardiomyopathy (myocarditis): report from two expert committees on histology and viral cardiomyopathy. Heartbeat 1999, 4:3-4.
7. Maisch B., Portig I., Ristic A., et al. Definition of inflammatory cardiomyopathy (myocarditis): on the way to consensus. Herz 2000, 25:200-209.
8. Burkett E.L., Hershberger R.E. Clinical and genetic issues in familial dilated cardiomyopathy. J Am Coll Cardiol 2005, 45:969-981.
9. Pankuweit S., Portig I., Eckhardt H., et al. Prevalence of viral genome in endomyocardial biopsies from patients with inflammatory heart muscle disease. Herz 2000, 25:221-226.
10. Arbustini E., Morbini P., Pilotto A., et al. Familial dilated cardiomyopathy: from clinical presentation to molecular genetics. Am J Hum Genet 2001, 69:249-260.
11. Mason J.W. Myocarditis and dilated cardiomyopathy: an inflammatory link. Cardiovasc Res 2003, 60:5-10.
12. Shaw T., Elliot P., McKenna W.J. Dilated cardiomyopathy: a genetically heterogeneous disease. Lancet 2002, 360:654-655.
13. Maron B.J., Towbin J.A., Thiene G., et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association scientific statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 2006, 113:1807-1816.
14. Elliott P., Andersson B., Arbustini E., et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2008, 29:270-276.
15. Pankuweit S., Richter A., Ruppert V., et al. Classification of cardiomyopathies and indication for endomyocardial biopsy revisited. Herz 2009, 34:55-62.
16. Maisch B., Richter A., Koelsch S., et al. Management of patients with suspected (peri-)myocarditis and inflammatory dilated cardiomyopathy. Herz 2006, 31:881-890.
17. Cooper L.T., Baughman K.L., Feldman A.M., et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation 2007, 116:2216-2233.
18. Keren A., Syrris P., McKenna W.J. Hypertrophic cardiomyopathy: the genetic determinants of clinical disease expression. Nat Clin Pract Cardiovasc Med 2008, 5(3):158-168.
19. Marian A.J. Hypertrophic cardiomyopathy: from genetics to treatment. Eur J Clin Invest 2010, 40(4):360-369.
20. Rickers C., Wilke N.M., Jerosch-Herold M., et al. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation 2005, 112:855-861.
21. Schulz-Menger J., Maisch B., Abdel-Aty H., et al. Integrated biomarkers in cardiomyopathies: cardiovascular magnetic resonance imaging combined with molecular and immunologic markers. A stepwise approach for diagnosis and treatment. Herz 2007, 32:458-472.
22. Mestroni L., Maisch B., McKenna W.J., et al. Guidelines for the study of familial dilated cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyopathy. Eur Heart J 1999, 20(2):93-102.
23. Pankuweit S., Moll R., Baandrup U., et al. Prevalence of the parvovirus B19 genome in endomyocardial biopsy specimens. Hum Pathol 2003, 34:497-503.
24. Kühl U., Pauschinger M., Noutsias M., et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with " idiopathic" left ventricular dysfunction. Circulation 2005, 11:887-893.
25. Küthe F., Lindner J., Matwschke K., et al. Prevalence of parvovirus B19 and human Bocavirus DNA in the heart of patients with no evidence of dilated cardiomyopathy or myocarditis. Clin Infect Dis 2009, 49:1660-1666.
26. Stewart G.C., Lopez-Molina J., Gottumukkala R.V., et al. Myocardial parvovirus B19 persistence: lack of association with clinicopathologic phenotype in adults with heart failure. Circ Heart Fail 2011, 4(1):71-78.
27. Kindermann I., Kindermann M., Kandolf R., et al. Predictors of outcome in patients with suspected myocarditis. Circulation 2008, 118:639-648.
28. Maisch B., Richter A., Sandmöller A., et al. BMBF-Heart Failure Network. Inflammatory dilated cardiomyopathy (DCMI). Herz 2005, 30:535-544.
29. Maisch B., Ristic A.D., Hufnagel G., et al. Dilated cardiomyopathies as a cause of congestive heart failure. Herz 2002, 27:113-134.
30. Maisch B., Ristic A.D., Portig I., et al. Human viral cardiomyopathy. Front Biosci 2003, 8:S39-S67.
31. Maisch B., Outzen H., Roth D., et al. Prognostic determinants in conventionally treated myocarditis and perimyocarditis-focus on antimyolemmal antibodies. Eur Heart J 1991, 12(Suppl B):81-87.
32. Liebermann E.B., Hutchin G.M., Herskowitz A., et al. Clinico-pathologic description of myocarditis. J Am Coll Cardiol 1991, 18:1617-1626.
33. Friedrich M.G., Strohm O., Schulz-Menger J., et al. Contrast media-enhanced magnetic resonance imaging visualizes myocardial changes in the course of viral myocarditis. Circulation 1998, 97:1802-1809.
34. Laissy J.P., Messin B., Varenne O., et al. MRI of acute myocarditis: a comprehensive approach based on various imaging sequences. Chest 2002, 122:1638-1648.
35. Mahrholdt H., Goedecke C., Wagner A., et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation 2004, 109:1250-1258.
36. Abdel-Aty H., Boye P., Zagrosek A., et al. Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. J Am Coll Cardiol 2005, 45:1815-1822.
37. Friedrich M.G., Sechtem U., Schulz-Menger J., et al. Cardiovascular magnetic resonance in myocarditis: a JACC White Paper. J Am Coll Cardiol 2009, 53:1475-1487.
38. Maisch B, Alter P, Romminger M, et al. MRI or EMB for the diagnosis of myocarditis and viral heart disease. Abstracts of the ESC Congress. 2011.
39. Maisch B., Seferovic P.M., Ristic A.D., et al. Task Force on the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology. Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task Force on the diagnosis and management of pericardial diseases of the European Society of Cardiology. Eur Heart J 2004, 25(7):587-610.
40. Horowitz M.D., Schultz C.S., Stinson E.B., et al. Sensitivity and specificity of echocardiographic diagnosis of pericardial effusion. Circulation 1974, 50:239-245.
41. Aretz H.T., Billingham M., Olsen E., et al. Myocarditis: the Dallas criteria. Hum Pathol 1987, 18:619-624.
42. Baughman K.L. Diagnosis of myocarditis: death of Dallas criteria. Circulation 2006, 113:593-595.
43. Maisch B., Hufnagel G., Schönian U., et al. The European Study of Epidemiology and Treatment of Cardiac Inflammatory Disease (ESETCID). Eur Heart J 1995, 16(Suppl 0):173-175.
44. Woodruff J.F., Woodruff J.J. Involvement of T lymphocytes in the pathogenesis of coxsackie virus B3 heart disease. J Immunol 1974, 113:1726-1734.
45. Woodruff J.F. Viral myocarditis. A review. Am J Pathol 1980, 101:425-484.
46. Wolfgram L.J., Beisel K.W., Herskowitz A., et al. Variations in the susceptibility to Coxsackievirus B3-induced myocarditis among different strains of mice. J Immunol 1986, 136:1846-1852.
47. Huber S.A., Lodge P.A. Coxsackievirus B-3-myocarditis. Identification of different pathogenic mechanisms in DBA/2 and Balb/c mice. Am J Pathol 1986, 122:284-291.
48. Chow L.H., Gauntt C.J., McManus B.M. Differential effects of myocarditic variants of Coxsackievirus B3 in inbred mice. A pathologic characterization of heart tissue damage. Lab Invest 1991, 64:55-64.
49. Bergelson J.M., Cunningham J.A., Droguett G., et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997, 275:1320-1323.
50. Bergelson J.M., Chan M., Solomon K.R., et al. Decay accelerating factor (CD55), a glycosylphosphatidylinositol-anchored complement regulatory protein, is a receptor for several echoviruses. Proc Natl Acad Sci U S A 1994, 91:6245-6249.
51. Klingel K., Kandolf R. The role of enterovirus replication in the development of acute and chronic heart muscle disease in different immunocompetent mouse strains. Scand J Infect Dis Suppl 1993, 88:79-85.
52. Wessely R., Henke A., Zell R., et al. Low-level expression of a mutant coxsackieviral cDNA induces a myocytopathic effect in culture: an approach to the study of enteroviral persistence in cardiac myocytes. Circulation 1998, 98:450-457.
53. McManus B.M., Chow L.H., Wilson J.E., et al. Direct myocardial injury by enterovirus: a central role in the evolution of murine myocarditis. Clin Immunol Immunopathol 1993, 68:159-169.
54. Ruppert V., Meyer T., Pankuweit S., et al. Activation of STAT1-transcription factor precedes up-regulation of coxsackievirus-adenovirus receptor during viral myocarditis. Cardiovasc Pathol 2008, 17:81-92.
55. Li J., Schwimmbeck P.L., Tschöpe C., et al. Collagen degradation in a murine myocarditis model: relevance of matrix metalloproteinase in association with inflammatory induction. Cardiovasc Res 2002, 56:235-247.
56. Kishimoto C., Kawamata H., Sakai S., et al. Role of MIP-2 in coxsackievirus B3 myocarditis. J Mol Cell Cardiol 2000, 32:631-638.
57. Seko Y., Takahashi N., Yagita H., et al. Expression of cytokine mRNAs in murine hearts with acute myocarditis caused by coxsackievirus b3. J Pathol 1997, 183:105-108.
58. Huber S.A., Budd R.C., Rossner K., et al. Apoptosis in coxsackievirus B3-induced myocarditis and dilated cardiomyopathy. Ann N Y Acad Sci 1999, 887:181-190.
59. Badorff C., Lee G.H., Lamphear B.J., et al. Enteroviral protease2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med 1999, 5:320-326.
60. Fuse K., Chan G., Liu Y., et al. Myeloid differentiation factor-88 plays a crucial role in the pathogenesis of Coxsackievirus B3-induced myocarditis and influences type I interferon production. Circulation 2005, 112:2276-2285.
61. Fairwheather D., Rose N.R. Coxsackievirus-induced myocarditis in mice: a model of autoimmune disease for studying immunotoxicity. Methods 2007, 41:118-122.
62. Frisancho-Kiss S., Davis S.E., Nyland J.F., et al. Cutting edge: cross-regulation by TLR4 and T cell Ig mucin-3 determines sex differences in inflammatory heart disease. J Immunol 2007, 178:6710-6714.
63. Godeny E.K., Gauntt C.J. Murine natural killer cells limit coxsackievirus B3 replication. J Immunol 1987, 139:913-918.
64. Seko Y., Tsuchimochi H., Nakamura T., et al. Expression of major histocompatibility complex class I antigen in murine ventricular myocytes infected with Coxsackievirus B3. Circ Res 1990, 67:360-367.
65. Seko Y., Matsuda H., Kato K., et al. Expression of intercellular adhesion molecule-1 in murine hearts with acute myocarditis caused by coxsackievirus B3. J Clin Invest 1993, 91:1327-1336.
66. Seko Y., Yagita H., Okumura K., et al. T-cell receptor V beta expression in infiltrating cells in murine hearts with acute myocarditis caused by coxsackievirus B3. Circulation 1994, 89:2170-2175.
67. Li K., Xu W., Guo Q., et al. Differential macrophage polarization in male and female BALB/c mice infected with coxsackievirus B3 defines susceptibility to viral myocarditis. Circ Res 2009, 105:353-364.
68. Huber S.A., Feldman A.M., Sartini D. Coxsackievirus B3 induces T regulatory cells, which inhibit cardiomyopathy in tumor necrosis factor-alpha transgenic mice. Circ Res 2006, 99:1109-1116.
69. Huber S.A., Job L.P. Cellular immune mechanisms in Coxsackievirus group B, type 3 included myocarditis in BALB/C mice. Adv Exp Med Biol 1983, 161:491-508.
70. Seko Y., Takahashi N., Ishiyama S., et al. Expression of costimulatory molecules B7-1, B7-2, and CD40 in the heart of patients with acute myocarditis and dilated cardiomyopathy. Circulation 1998, 97:637-639.
71. Takata S., Nakamura H., Umemoto S., et al. Identification of autoantibodies with the corresponding antigen for repetitive coxsackievirus infection-induced cardiomyopathy. Circ J 2004, 68:677-682.
72. Latif N., Baker C.S., Dunn M.J., et al. Frequency and specificity of antiheart antibodies in patients with dilated cardiomyopathy detected using SDS-PAGE and western blotting. J Am Coll Cardiol 1993, 22:1378-1384.
73. Latif N., Zhang H., Archard L.C., et al. Characterization of anti-heart antibodies in mice after infection with coxsackie B3 virus. Clin Immunol 1999, 91:90-98.
74. Maisch B., Drude L., Hengstenberg C., et al. Are antisarcolemmal (ASAs) and antimyolemmal antibodies (AMLAs) " natural" antibodies?. Basic Res Cardiol 1991, 86(Suppl 3):101-114.
75. Maisch B., Bauer E., Cirsi M., et al. Cytolytic cross-reactive antibodies directed against the cardiac membrane and viral proteins in coxsackievirus B3 and B4 myocarditis. Characterization and pathogenetic relevance. Circulation 1993, 87(Suppl 5):IV49-IV65.
76. Maisch B., Berg P.A., Kochsiek K. Autoantibodies and serum inhibition factors (SIF) in patients with myocarditis. Klin Wochenschr 1980, 58(5):219-225.
77. Maisch B., Berg P.A., Kochsiek K. Immunological parameters in patients with congestive cardiomyopathy. Basic Res Cardiol 1980, 75:221-222.
78. Maisch B., Bülowius U., Schmier K., et al. Immunological cellular regulator and effector mechanisms in myocarditis. Herz 1985, 10:8-14.
79. Maisch B., Dienesch C.H., Wendl I. Effect of leukotrienes on isolated vital cardiac cells-an in vitro model of cardiocytotoxic mediators in inflammation?. Eur Heart J 1997, 8(Suppl J):463-465.
80. Maisch B., Drude L., Hengstenberg C., et al. Cytolytic anticardiac membrane antibodies in the pathogenesis of myopericarditis. Postgrad Med J 1992, 68(Suppl 1):11-16.
81. Maisch B., Herzum M., Schönian U. Immunomodulating factors and immunosuppressive drugs in the therapy of myocarditis. Scand J Infect Dis Suppl 1993, 88:149-162.
82. Maisch B., Lotze U., Schneider J., et al. Antibodies to human sinus node in sick-sinus syndrome. Pacing Clin Electrophysiol 1986, 9(6 Pt 2):1101-1109.
83. Maisch B., Ristic A.D., Hufnagel G., et al. Pathophysiology of viral myocarditis: the role of humoral immune response. Cardiovasc Pathol 2002, 11(2):112-122.
84. Maisch B., Trostel-Soeder R., Berg P.A., et al. Assessment of antibody mediated cytolysis of vital adult cardiocytes isolated by centrifugation in a continuous gradient of Percoll TM in patients with acute myocarditis. J Immunol Methods 1981, 44:159-169.
85. Maisch B., Trostel-Soeder R., Stechemesser E., et al. Diagnostic relevance of humoral and cell-mediated immune reactions in patients with acute viral myocarditis. Clin Exp Immunol 1982, 48:533-545.
86. Maisch B., Wedeking U., Kochsiek K. Quantitative assessment of antilaminin antibodies in myocarditis and perimyocarditis. Eur Heart J 1987, 8(Suppl J):223-235.
87. Maisch B. Autoreactivity to the cardiac myocyte, connective tissue and the extracellular matrix in heart disease and postcardiac injury. Springer Semin Immunopathol 1989, 11:369-395.
88. Maisch B. Surface antigens of adult heart cells and their use in diagnosis. Basic Res Cardiol 1985, 80(Suppl 1):47-52.
89. Maisch B. The sarcolemma as antigen in the secondary immunopathogenesis of myopericarditis. Eur Heart J 1987, 8(Suppl J):155-165.
90. Magnusson Y., Wallukat G., Waagstein F., et al. Autoimmunity in idiopathic dilated cardiomyopathy. Characterization of antibodies against the beta1-adrenoceptor with positive chronotropic effect. Circulation 1994, 89:2760-2767.
91. Wallukat G., Wollenberg A., Morwinski R., et al. Anti-beta1-adrenoceptor autoantibodies with chronotropic activity from the serum of patients with dilated cardiomyopathy: mapping of epitopes in the first and second extracellular loops. J Mol Cell Cardiol 1995, 27:397-406.
92. Jahns R., Boivin V., Siegmund C., et al. Autoantibodies activating human beta 1-adrenergic receptors are associated with reduced cardiac function in chronic heart failure. Circulation 1999, 99:649-654.
93. Fu L.X., Magnusson Y., Bergh C.H., et al. Localization of a functional autoimmune epitope on the second extracellular loop of the human muscarinic acetylcholin receptor 2 in patients with idiopathic dilated cardiomyopathy. J Clin Invest 1993, 91:1964-1968.
94. Christ T., Wettwer E., Dobrev D., et al. Autoantibodies against the beta1-adrenoceptor from patients with dilated cadiomyopathy prolong action potential duration and enhance contractility in isolated cardiomyocytes. J Mol Cell Cardiol 2001, 33:1515-1525.
95. 2+ current in rat ventricular myocytes. J Mol Cell Cardiol 2006, 41:716-723.
96. Jahns R., Boivin V., Krapf T., et al. Modulation of beta1-adrenoceptor activity by domain-specific antibodies and heart failure associated autoantibodies. J Am Coll Cardiol 2000, 36:1280-1287.
97. Jahns R., Bovin V., Hein L., et al. Direct evidence for a beta1-adrenergic receptor directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin invest 2004, 113:1419-1429.
98. Lotze U., Maisch B. Humoral immune response to cardiac conducting tissue. Springer Semin Immunopathol 1989, 11:409-422.
99. Caforio A.L., Mahon N.J., Tona F., et al. Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance. Eur J Heart Fail 2002, 4:411-417.
100. Klein R., Maisch B., Kochsiek K., et al. Demonstration of organ specific antibodies against heart mitochondria (anti M7) in sera from patients with some forms of heart diseases. Clin Exp Immunol 1984, 58:283-292.
101. Pohlner K., Portig I., Pankuweit S., et al. Identification of mitochondrial antigens recognized by the antibodies in sera of patients with dilated cardiomyopathy by two-dimensional gel electrophoresis and protein sequencing. Am J Cardiol 1997, 80:1040-1045.
102. Schultheiss H.P., Bolte H.D. Immunological analysis of autoantibodies against the adenine nucleotide translocator in dilated cardiomyopathy. J Mol Cell Cardiol 1988, 17:603-617.
103. Schulze K., Witzenbichler B., Christmann C., et al. Disturbance of myocardial energy metabolism in experimental virus myocarditis by antibodies against the adenin nucleotide translocator. Cardiovasc Res 1999, 44:91-100.
104. Gluck B., Schmidtke M., Merkle I., et al. Persistent expression of cytokines in the chronic stage of CVB3-induced myocarditis in NMRI mice. J Mol Cell Cardiol 2001, 33:1615-1626.
105. Young N.S., Brown K.E. Mechanisms of disease. Parvovirus B19. N Engl J Med 2004, 350:586-597.
106. Lamparter S., Schoppet M., Pankuweit S., et al. Acute parvovirus B19 infection associated with myocarditis in an immunocompetent adult. Hum Pathol 2003, 34(7):725-728.
107. Saint-Martin I., Choulot J.J., Bonnau E., et al. Myocarditis caused by parvovirus. J Pediatr 1990, 116:1007-1008.
108. Nigro G., Bastianon V., Colloridl V., et al. Human parvovirus B19 infection in infancy associated with acute and chronic lymphocytic myocarditis and high cytokine levels: report of 3 cases and review. Clin Infect Dis 2000, 13:65-69.
109. Schowengerdt K.O., Ni J., Denfield S.W., et al. Association of parvovirus B19 genome in children with myocarditis and cardiac allograft rejection: diagnosis using the polymerase chain reaction. Circulation 1997, 96(10):3549-3554.
110. Bock C.T., Klingel K., Kandolf R. Human parvovirus B19-associated myocarditis. N Engl J Med 2010, 362:213-214.
111. Salahuddin S.Z. Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders. Science 1986, 234(4776):596-601.
112. Krueger G.R., Ablashi D.V. Human herpesvirus-6: a short review of its biological behavior. Intervirology 2003, 46:257-269.
113. Buja L.M. HHV-6 in cardiovascular pathology. In: Krueger GRF. Human herpesvirus-6 2006, 137. Elsevier Science Publ, Amsterdam (London). 2nd edition. D.V. Ablashi (Ed.).
114. Fukae S., Ashizawa N., Morikawa S., et al. A fatal fulminant myocarditis with human herpesvirus-6 infection. Intern Med 2000, 39:632-636.
115. De Ona M., Melon S., Rodriguez J.L., et al. Association between human herpesvirus type 6 and type 7, and cytomegalovirus disease in heart transplant recipients. Transplant Proc 2002, 34:75-76.
116. Komaroff A.L. Is human herpesvirus-6 a trigger for chronic fatigue syndrome?. J Clin Virol 2006, 37(Suppl 1):S39-S46.
117. Schönian U., Crombach M., Maisch B. Assessment of cytomegalovirus DNA and protein expression in patients with myocarditis. Clin Immunol Immunopathol 1993, 68:229-233.
118. Schönian U., Crombach M., Maisch B. Does CMV infection play a role in myocarditis? New aspects from in-situ hybridization. Eur Heart J 1991, 12(Suppl D):65-68.
119. Matsumori A., Yutani C., Ikeda Y., et al. Hepatitis C virus from the hearts of patients with myocarditis and cardiomyopathy. Lab Invest 2000, 80(7):1137-1142.
120. Barbaro G., Di Lorenzo G., Soldini M., et al. Intensity of myocardial expression of inducible nitric oxide synthase influences the clinical course of human immunodeficiency virus-associated cardiomyopathy. Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS (GISCA). Circulation 1999, 100(9):933-939.
121. Sprenger M.J., Van Naelten M.A., Mulder P.G., et al. Influenza mortality and excess deaths in the elderly 1967-1982. Epidemiol Infect 1989, 103:633-641.
122. Herskowitz A., Campbell S., Deckers J., et al. Demographic features and prevalence of idiopathic myocarditis in patients undergoing endomyocardial biopsy. Am J Cardiol 1993, 71:982-986.
123. Ozkutlu S., Soylemezoglu O., Calikoglu A.S., et al. Fatal mumps myocarditis. Jpn Heart J 1989, 30:109-114.
124. Ward S.C., Wiselka M.J., Nicholson K.G. Still's disease and myocarditis associated with recent mumps infection. Postgrad Med J 1988, 64:693-695.
125. Martin J.T., Kugler J.D., Gumbiner C.H., et al. Refractory congestive heart failure after ribavirin in infants with heart disease and respiratory syncytial virus. Nebr Med J 1990, 75:23-26.
126. Matthews A.W., Griffiths I.D. Post-vaccinal pericarditis and myocarditis. Br Heart J 1974, 36:1043-1047.
127. Finlay-Jones L.R. Fatal myocarditis after vaccinations for smallpox. N Engl J Med 1964, 270:41-42.
128. Pauschinger M., Bowles N.E., Fuentes-Garcia F.J., et al. Detection of adenoviral genome in the myocardium of adult patients with idiopathic left ventricular dysfunction. Circulation 1999, 99:1348-1354.
129. Hunt S.A., Baker D.W., Chin M.H., et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure); International Society for Heart and Lung Transplantation; Heart Failure Society of America. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Circulation 2001, 104:2996-3007.
130. Dickstein K., Cohen-Solal A., Filippatos G., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008, 10:933-989.
131. Mason J.W., O'Connell J.B., Herskowitz A., et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 1995, 333:269-275.
132. Maisch B., Camerini F., Schultheiss H.P. Immunosuppressive therapy for myocarditis. N Engl J Med 1995, 333:1713. [letter].
133. Hufnagel G., Pankuweit S., Richter A., for the ESETCID investigators, et al. The European study of epidemiology and treatment of cardiac inflammatory diseases (ESETCID): first epidemiological results. Herz 2000, 25(3):279-285.
134. Wojnicz R., Nowalany-Kozielska E., Wojciechowska C., et al. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation 2001, 104:39-45.
135. Frustaci A., Chimenti C., Calabrese F., et al. Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation 2003, 107:857-863.
136. Frustaci A., Russo M.A., Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J 2009, 30:1995-2002.
137. Schultheiss H.P., Noutsias M., Kuehl U. Antiviral interferon-ß treatment in patients with chronic viral cardiomyopathy. Inflammatory cardiomyopathy (DCMi)-pathogenesis and therapy 2011, 265-278. Birkhäuser & Springer Basel AG. H.P. Schultheiß, M. Noutsias (Eds.).
138. Takada H., Kishimoto C., Hiraoka Y. Therapy with immunoglobin suppresses myocarditis in a murine coxsackievirus B3 model. Antiviral and anti-inflammatory effects. Circulation 1995, 92:1604-1611.
139. McNamara D.M., Holubkov R., Starling R.C., et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation 2001, 103:2254-2259.
140. Anthony R.M., Nimmerjahn F., Ashline D.J., et al. Recapitulation of IVIG anti-inflammatory activity with a recombinant Ig Fc. Science 2008, 320:373-376.
141. Marcus F.I., Fontaine G.H., Guiraudon G., et al. Right ventricular dysplasia: a report of 24 adult cases. Circulation 1982, 65:384-398.
142. Thiene G., Nava A., Corrado D., et al. Right ventricular cardiomyopathy and sudden death in young people. N Engl J Med 1988, 318:129-133.
143. Nava A., Bauce B., Basso C., et al. Clinical profile and long-term follow-up of 37 families with arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol 2000, 36:2226-2233.
144. Delmar M., McKenna W.J. The cardiac desmosome and arrhythmogenic cardiomyopathies: from gene to disease. Circ Res 2010, 107(6):700-714.
145. Herren T., Gerber P.A., Duru F. Arrhythmogenic right ventricular cardiomyopathy/dysplasia: a not so rare " disease of the desmosome" with multiple clinical presentations. Clin Res Cardiol 2009, 98(3):141-158.
146. Sen-Chowdhry S., Syrris P., McKenna W.J. Role of genetic analysis in the management of patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol 2007, 50(19):1813-1821.
147. Marcus F.I., McKennae W.J., Sherill D., et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia. Eur Heart J 2010, 31:806-814.